Avadomide联合奥妥珠单抗治疗复发或难治性B细胞非霍奇金淋巴瘤(CC-122-NHL-001):一项多中心剂量递增和扩展1期研究
这项1b期剂量递增和扩展研究在法国、意大利和荷兰的8个中心纳入73例复发或难治性CD20阳性B细胞非霍奇金淋巴瘤患者,评估Avadomide联合奥妥珠单抗的安全性和初步活性。Avadomide推荐2期剂量为3.0 mg配方胶囊、5-7天方案联合奥妥珠单抗1000 mg。最常见≥3级不良事件为中性粒细胞减少(41/73,56%)和血小板减少(17/73,23%)。
要点
- Avadomide推荐2期剂量为3.0 mg配方胶囊、5-7天方案联合奥妥珠单抗1000 mg。
- 最常见≥3级不良事件为中性粒细胞减少(41/73,56%)和血小板减少(17/73,23%)。
- 研究未达到预设活性阈值,但作者认为该无化疗方案值得进一步研究。
核心结论
- Avadomide联合奥妥珠单抗毒性可控,对大多数患者是可耐受的治疗选择。
- 尽管试验未达到预设活性阈值,作者认为 cereblon 调节剂联合下一代抗CD20抗体在经重度治疗的复发或难治性非霍奇金淋巴瘤中值得进一步研究作为无化疗选择。
研究设计与样本
- CC-122-NHL-001是一项在法国、意大利和荷兰8个中心开展的1b期剂量递增和扩展研究。
- 纳入年龄≥18岁、组织学确诊CD20阳性复发或难治性非霍奇金淋巴瘤、ECOG体能状态0或1、既往接受过治疗的患者。
- 剂量扩展阶段仅纳入既往治疗过的复发或难治性滤泡性淋巴瘤(1、2或3a级)患者。
- Avadomide以递增剂量和两种制剂给药:原料药胶囊1.0 mg、2.0 mg、3.0 mg和4.0 mg,以及配方胶囊3.0 mg和4.0 mg,口服每日一次,第1-5天给药后休息2天(5-7天方案),每28天周期的每周给药。
- 奥妥珠单抗1000 mg静脉给药,第1周期第2、8、15天及第2-8周期第1天给药。
主要发现
- 2015年6月24日至2018年12月5日,共73例患者入组并接受治疗;19例弥漫大B细胞淋巴瘤,53例滤泡性淋巴瘤,1例边缘区淋巴瘤。
- 中位随访253天(IQR 127-448),中位既往抗癌方案数为3(IQR 2-4)。
- 剂量递增阶段未达到最大耐受剂量和不可耐受剂量。
- 基于安全性和药代动力学-药效学数据,Avadomide的RP2D确定为3.0 mg配方胶囊、5-7天方案联合奥妥珠单抗1000 mg。
- 所有剂量下3例患者发生剂量限制性毒性;RP2D治疗中1例患者发生剂量限制性毒性(3级脓毒症)。
关键数值与推荐
- Avadomide推荐2期剂量为3.0 mg配方胶囊、5-7天方案联合奥妥珠单抗1000 mg。
- 剂量递增阶段未达到最大耐受剂量和不可耐受剂量。
- 所有剂量下3例患者发生剂量限制性毒性;RP2D治疗中1例患者发生剂量限制性毒性(3级脓毒症)。
临床怎么用
- 作者认为Avadomide联合奥妥珠单抗毒性可控,对大多数患者是可耐受的治疗选择。
- 作者认为该联合方案的初步抗肿瘤活性值得进一步研究作为经重度治疗的复发或难治性非霍奇金淋巴瘤的无化疗选择。
局限性
- 试验未达到预设活性阈值。
- 作者认为需进一步研究以评估cereblon调节剂联合下一代抗CD20抗体的初步抗肿瘤活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Avadomide (CC-122) is a novel oral cereblon-modulating agent with promising activity in non-Hodgkin lymphoma. We aimed to examine the safety and preliminary activity of avadomide plus obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma. METHODS: CC-122-NHL-001 was a phase 1b dose escalation and expansion study at eight sites in France, Italy, and the Netherlands. Eligible patients (aged ≥18 years) had histologically confirmed CD20-positive relapsed or refractory non-Hodgkin lymphoma, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had received previous treatment. In the dose expansion phase, only patients with previously treated relapsed or refractory follicular lymphoma (grade 1, 2, or 3a) were included. Avadomide was administered in escalating doses and two formulations: active pharmaceutical ingredient in capsule in 1·0 mg, 2·0 mg, 3·0 mg, and 4·0 mg doses and as formulated capsules in 3·0 mg and 4·0 mg doses orally once daily on days 1-5 followed by 2 days off (5-7-day schedule) every week of each 28-day cycle. Obinutuzumab 1000 mg was administered intravenously on days 2, 8, and 15 of cycle 1 and day 1 of cycles 2-8. Primary objectives were to determine the safety and tolerability, the non-tolerated dose, maximum tolerated dose, and recommended phase 2 dose (RP2D). All patients who received treatment were included in the safety analyses. Efficacy-evaluable patients completed at least one cycle of treatment and had baseline and at least one post-baseline assessment. The study is registered with ClinicalTrials.gov, NCT02417285 and EudraCT 2014-003333-26, and is ongoing. FINDINGS: Between June 24, 2015, and Dec 5, 2018, 73 patients were enrolled and treated; 19 had diffuse large B-cell lymphoma, 53 follicular lymphoma, and one marginal zone lymphoma. Median follow-up was 253 days (IQR 127-448). The median number of previous anticancer regimens was three (IQR 2-4). The maximum tolerated dose and non-tolerated dose were not reached in the dose escalation phase. On the basis of safety and pharmacokinetic-pharmacodynamic data, the avadomide RP2D was established as 3·0 mg as formulated capsules on a 5-7-day schedule in combination with 1000 mg of obinutuzumab. Patients enrolled in the expansion cohort received the established RP2D of avadomide. Across all doses, three patients had dose-limiting toxicities; one patient treated at the RP2D had dose-limiting toxicity (grade 3 sepsis). The most common adverse events of grade 3 and above were neutropenia (41 [56%] of 73) and thrombocytopenia (17 [23%] of 73). 34 (47%) patients had serious adverse events, which were considered to be avadomide-related in 23 (32%) of 73 patients and obinutuzumab-related in 20 (27%) of 73 patients. Two treatment-related deaths occurred, one owing to tumour flare and one from acute myeloid leukaemia after study discontinuation. INTERPRETATION: Avadomide plus obinutuzumab has a manageable toxicity, being a tolerable treatment option for most patients. Although the prespecified threshold for activity was not met in the trial, we believe that the preliminary antitumour activity of cereblon modulators plus next-generation anti-CD20 antibodies in heavily pretreated relapsed or refractory non-Hodgkin lymphoma warrants further investigation as a chemotherapy-free option in this setting. FUNDING: Celgene Corporation.
引用
- Michot JM, Bouabdallah R, Vitolo U, et al. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet Haematol. 2020. PMID: 32758434. doi:10.1016/S2352-3026(20)30208-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。